Will the FDA approve intismeran autogene (V940/mRNA-4157)?

Open

intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma

Selected outcome

Before Oct 1, 2027

68%

Before Oct 1, 2027 · 68%

Stored quote · checking the venue

Price

Loading price history.

Before Oct 1, 2027
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?
68%
Open · ~$51 24h · ~$602 vol
Bid 64¢ · Ask 71¢
Open full market view →
Before Apr 1, 2027
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Apr 1, 2027?
No quote
Open · ~$0 24h · ~$0 vol
Ask 8¢
Open full market view →
Before Jul 1, 2027
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027?
14%
Open · ~$0 24h · ~$3 vol
Bid 9¢ · Ask 18¢
Open full market view →
Before Jan 1, 2028
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?
88%
Open · ~$0 24h · ~$867 vol
Bid 83¢ · Ask 92¢
Open full market view →
Before Jul 1, 2028
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2028?
95%
Open · ~$0 24h · ~$0 vol
Bid 91¢ · Ask 99¢
Open full market view →

Event statistics